Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy

References

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–2795.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849.
   PubMed Web of Science ®Google Scholar
• Harris NL, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392.
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Yri OE, Kimby E, et al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol. 2012;156:225–233.
   PubMed Web of Science ®Google Scholar
• Horn H, Kohler C, Witzig R, et al. Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. Haematologica. 2018;103:1182–1190.
   PubMed Web of Science ®Google Scholar
• Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116:3797–3806.
   PubMed Web of Science ®Google Scholar
• Mustafa Ali M, Rybicki L, Nomani L, et al. Grade 3 follicular lymphoma: outcomes in the rituximab era. Clin Lymphoma Myeloma Leuk. 2017;17:797–803.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012;30:3368–3375.
   PubMed Web of Science ®Google Scholar
• Sancho J-M, García O, Mercadal S, et al. The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. Leuk Res. 2015;39:853–858.
   PubMed Web of Science ®Google Scholar
• Shustik J, Quinn M, Connors JM, et al. Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol. 2011;22:1164–1169.
   PubMed Web of Science ®Google Scholar
• Hans CP, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood. 2003;101:2363–2367.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–4562.
   PubMed Web of Science ®Google Scholar
• Koch K, Hoster E, Ziepert M, et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol. 2016;27:1323–1329.
   PubMed Web of Science ®Google Scholar
• Maeshima AM, Taniguchi H, Nomoto J, et al. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy. Hum Pathol. 2013;44:2529–2535.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Feng L, Pro B, et al. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol. 2008;19:553–559.
   PubMed Web of Science ®Google Scholar
• MacManus M, et al. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018;36:2918–2925.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. B-Cell Lymphomas Version 4.2018. [cited 2018 May 15]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.
   Google Scholar
• Vargo JA, Gill BS, Balasubramani GK, et al. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer. 2015;121:3325–3334.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15:457–463.
   PubMed Web of Science ®Google Scholar
• Cencini E, Puccini B, Rigacci L, et al. Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma. Leuk Lymphoma. 2018;59:1420–1426.
   PubMed Web of Science ®Google Scholar
• Janikova A, Bortlicek Z, Campr V, et al. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy? Leuk Lymphoma. 2015;56:2350–2356.
   PubMed Web of Science ®Google Scholar
• Ruella M, Filippi AR, Bruna R, et al. Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study. Int J Radiat Oncol Biol Phys. 2016;94:783–791.
   PubMed Web of Science ®Google Scholar
• Dabaja B. Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II. 2013; Available from: https://clinicaltrials.gov/ct2/show/NCT01473628.
   Google Scholar
• Horn H, Schmelter C, Leich E, et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 2011;96:1327–1334.
   PubMed Web of Science ®Google Scholar
• Yuan J, Greiner TC, Fu K, et al. Rituximab improves the outcome of patients with grade 3 follicular lymphoma receiving anthracycline-based therapy. Clin Lymphoma Myeloma Leuk. 2017;17:488–497 e2.
   PubMed Web of Science ®Google Scholar
• Ray S, Craig FE, Swerdlow SH. Abnormal patterns of antigenic expression in follicular lymphoma: a flow cytometric study. Am J Clin Pathol. 2005;124:576–583.
   PubMed Web of Science ®Google Scholar
• Guo Y, Karube K, Kawano R, et al. Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances. Leukemia. 2005;19:1058–1063.
   PubMed Web of Science ®Google Scholar
• Bilalovic N, Blystad AK, Golouh R, et al. Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am J Clin Pathol. 2004;121:34–42.
   PubMed Web of Science ®Google Scholar
• Eshoa C, Perkins S, Kampalath B, et al. Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas. Am J Clin Pathol. 2001;115:862–867.
   PubMed Web of Science ®Google Scholar
• Ngan BY, Chen-Levy Z, Weiss LM, et al. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med. 1988;318:1638–1644.
   PubMed Web of Science ®Google Scholar
• Pruneri G, Valentini S, Fabris S, et al. Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. Int J Cancer. 2004;112:71–77.
   PubMed Web of Science ®Google Scholar
• Wang SA, Wang L, Hochberg EP, et al. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol. 2005;29:1490–1496.
   PubMed Web of Science ®Google Scholar
• Lozanski G, et al. Inter-reader variability in follicular lymphoma grading: conventional and digital reading. J Pathol Inform. 2013;4:30.
   PubMedGoogle Scholar